Trials / Recruiting
RecruitingNCT07493044
An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
An Open-Label, Phase I Clinical Trial of GPC3-Targeted Chimeric Antigen Receptor Autologous T-Cell Injection (Super CAR-T) for the Treatment of Patients With Advanced Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
Detailed description
After the subjects signed the informed consent form,the tumor tissue was detected by immunohistochemistry. The subjects could proceed to the subsequent clinical trial if the GPC3 immunohistochemistry was positive. Each subject received only one cell infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Super CAR-T | All participators received lymphoid-depleted preconditioning before Super CAR-T cells infusion. Super CAR-T cells were infused 3 days later. |
Timeline
- Start date
- 2026-03-20
- Primary completion
- 2028-04-30
- Completion
- 2028-07-30
- First posted
- 2026-03-25
- Last updated
- 2026-03-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07493044. Inclusion in this directory is not an endorsement.